iiinova — where your digital self keeps evolving

Reposted by Michael Fisch MD MPH

NEJM.org @nejm.org · 30/05/2025

Presented at #ASCO25: The addition of encorafenib and cetuximab to mFOLFOX6 chemotherapy improved outcomes in the primary treatment of metastatic BRAF V600E–mutated colorectal cancer. Full BREAKWATER phase 3 trial results:

nej.md

1239

Reposted by Michael Fisch MD MPH

Laura Esfeller @lauraesfeller.bsky.social · 03/05/2025

SWOG 2210 is open for #prostatecancer patients w/ BRCA1 or BRCA2. Fascinating to see BRCA’s role in other cancers. Hoping we see biomarkers unlock clues in RCC soon. #GUonc #oncsky #cansky

081

Reposted by Michael Fisch MD MPH

Mikkael Sekeres @mikkaelsekeres.bsky.social · 17/04/2025

So thrilled to be joined by @missmeganel.bsky.social to discuss her amazing essay “Tamales” in our latest @ascocancer.bsky.social #CancerStories podcast! Listen to how patients invite their doctors into their culture and their world. 🎗️♥️🇲🇽 ascopubs.org/do/tamales-cel…

063

Reposted by Michael Fisch MD MPH

JAMA @jama.com · 14/04/2025

"If palliative care clinicians walk the line between security and vulnerability, then they must expect to misstep sometimes." This Viewpoint explores why palliative care clinicians may be at increased risk for dismissal. #MedSky ja.ma/42bomND

ja.ma

Why Good Palliative Care Clinicians Get Fired

This Viewpoint discusses why palliative care clinicians may be fired despite good job performance.

284

Reposted by Michael Fisch MD MPH

Darren Dahly @statsepi.bsky.social · 21/03/2025

Clinician researchers should just remove the work "trend" from your vocabulary. Seriously! 😜 If what you are indicating by using that word is actually important, you will be able to find another way to describe it. I promise.

2131

Reposted by Michael Fisch MD MPH

Jeffrey Peppercorn MD @ethicsdoctorp.bsky.social · 13/03/2025

Cancer-Related Cognitive Impairment: A Practical Guide for Oncologists | JCO Oncology Practice ascopubs.org/doi/10.1200/...

ascopubs.org

032

Reposted by Michael Fisch MD MPH

Ryan Nipp, MD, MPH, MBA, FASCO @ryannipp.bsky.social · 16/02/2025

Resilience and the Fallacy of “One Size Fits All.” www.nejm.org/doi/abs/10.1... @nejm.org @harvardmed.bsky.social @danafarber.bsky.social #PallOnc #GeriOnc #PalliativeCare

022

Reposted by Michael Fisch MD MPH

Dr Joseph McCollom DO @realbowtiedoc.bsky.social · 19/02/2025

@fumikochino.bsky.social published in @ascocancer.bsky.social this important #pallonc study #Fintox 💰 is direct costs (e.g., copays) ➕ indirect costs (e.g., lost income) ➡️: ⬆️stress and skipping #cancer meds. 4 step #COST frame work ⬆️🗣️ 🔗: ascopubs.org/doi/10.1200/...

1125

Reposted by Michael Fisch MD MPH

Eric Widera, MD @ewidera.bsky.social · 20/02/2025

At some point the US will need to consider value when approving drugs (or at least deciding if we are going to pay for them).

2125

Reposted by Michael Fisch MD MPH

Andrew Vickers @vickersbiostats.bsky.social · 17/01/2025

re: cancer label for lo-risk cancer: either a) relabel "but ensure patients understand [need for] monitoring" or b) don't relabel "but ensure patients understand lesions are unlikely to cause problems, so surveillance is appropriate." We know a) works better then b). jamanetwork.com/journals/jam...

jamanetwork.com

Will Renaming Some Cancers as Noncancers Hurt or Help?

This Medical News article discusses the ongoing debate about whether the word cancer should be dropped from the names of indolent tumors of the prostate and breast.

031

Reposted by Michael Fisch MD MPH

Wafik S. El-Deiry, MD, PhD, FACP @weldeiry.bsky.social · 18/01/2025

Cancer affects all in some way. Change is coming after too brief a period of great leadership by Dr. Kimryn Rathmell. Whatever happens it is an honor to express a vision for the field of cancer research & innovation in oncology. Research on causes & cures brings hope for patients.

062

Reposted by Michael Fisch MD MPH

Jia Luo, MD @jia-luo.bsky.social · 05/01/2025

I, too, have been surprised by the rise of "tornado plots" to plot clinical trial AEs at our conferences! 100% agree with ⬆️ this simple data vis change to improve interpretability of AEs.

081

Reposted by Michael Fisch MD MPH

Jarushka Naidoo @drjnaidoo.bsky.social · 14/12/2024

#ESMOImmuno24 Proffered paper🔥 Ph III CM73L: Nivo+cCRT➡️consol Nivo/Ipi v Nivo v cCRT➡️Durva @solangepeters.bsky.social - no PFS/OS benefit - g3+TRAE 57%, 54%, 49% - concerning pneumonitis signal Concurrent RT+IO - going going gone @oncoalert.bsky.social #LCSM #Medsky #Oncsky

12512

Reposted by Michael Fisch MD MPH

Dr. Don S Dizon @drdonsdizon.bsky.social · 14/12/2024

1/4 @swog.org lung cancer trial, PRAGMATICA, closes early! This randomized trial enrolled 800 volunteers w stage 3-4 lung cancer in 21 months (goal was 700 in 24m). Tested chemo vs ramicirumab/pembrolizumab. Not applicable to every trial, but...

1166

Reposted by Michael Fisch MD MPH

Prof Bogda Koczwara @bogda-koczwara.bsky.social · 13/12/2024

Hot of the press from @proteuspros - an infographic explaining the value of PROs! Note - they need to start as parr of the clinical encounter to benefit patients and society. tinyurl.com/3m594fhk

165

Reposted by Michael Fisch MD MPH

Ryan Nipp, MD, MPH, MBA, FASCO @ryannipp.bsky.social · 13/12/2024

Remote Symptom Monitoring of Patients With Advanced Lung #Cancer (The ProWide Study): A Randomized Controlled Trial. ascopubs.org/doi/10.1200/... @ascopost.bsky.social #LungCancer #PallOnc #SuppOnc

074

Reposted by Michael Fisch MD MPH

Wendy Woodward, MD, PhD @ibcradiation.bsky.social · 12/12/2024

De-escalation discussion on Europa trial tag line - which would you prefer, 5 days of RT or 5 years of ET…. 🤔🤔 No-brainer?? Supported by BASO II trial longer term data #SABC24

172

Reposted by Michael Fisch MD MPH

Sarah Sammons MD @drsarahsammons.bsky.social · 12/12/2024

This is great because patients hate endocrine therapy! However, we need to see recurrence data before adopting in the clinic. #BCSM #SABCS24

171

Reposted by Michael Fisch MD MPH

Tatiana Prowell, MD @tmprowell.bsky.social · 12/12/2024

#SABCS24 #bcsm #OncSky #RadOnc #MedSky BIG 2-04 SUPREMO: postmastectomy #radiation in int risk #breastcancer did not improve 10y overall survival, incl for node + subset. Stat sig but small ⬇️ in chest wall recurrence (2.5% -> 1.1% abs risk, NNT 63 to prevent 1 CW recurrence) @oncoalert.bsky.social

1186

Reposted by Michael Fisch MD MPH

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 12/12/2024

Omission of Axillary surgery continues to build momentum Here in pts w/ cN0 T1-2 invasive breast cancer—omission is noninferior to SLNB w 6 years med f/u Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial www.nejm.org/doi/full/10.... #SABCS24 @oncoalert.bsky.social @nejm.org

nejm.org

Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial | NEJM

Whether surgical axillary staging as part of breast-conserving therapy can be omitted without compromising survival has remained unclear. In this prospective, randomized, noninferiority trial, we i...

1174

Reposted by Michael Fisch MD MPH

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 12/12/2024

Dr. Singh draws nice comparisons between SOUND and INSEMA. #SABCS24 @oncoalert.bsky.social @sabcs.bsky.social

0124

Reposted by Michael Fisch MD MPH

Erika Hamilton MD, FASCO @erikahamilton9.bsky.social · 12/12/2024

It's a difficult topic to discuss- weight. Hugely personal, not easy to change, but impt. 4% ⬆️ recurrence in pts w/ node + #bcsm obese vs. lean 2% ⬆️ recurrence in pts with N0 dz 📌Magnitude of effect larger among premeno. 📌ER + AND ER neg @sabcs.bsky.social #SABCS24 @oncoalert.bsky.social

0217

Reposted by Michael Fisch MD MPH

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 12/12/2024

📌 PATINA: a Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + ET vs. Anti-HER2 Therapy + ET after Induction Treatment for Hormone Receptor-Positive (HR+)/HER-Positive Metastatic Breast Cancer #SABCS24 #day3 @oncoalert.bsky.social

0104

Reposted by Michael Fisch MD MPH

Dawn Hershman, MD, MS, FASCO @drdawnhershman.bsky.social · 12/12/2024

Better together- very excited about this @swog.org @alliancenctn.org #CTIU collaboration 🤝

094

Reposted by Michael Fisch MD MPH

Krishna Komanduri @drkomanduri.bsky.social · 08/12/2024

I never tire of seeing these progressively improved pediatric ALL survival curves, which represent one of the most remarkable achievements in all of medicine. Amazing to see even more improvement with bispecific antibody #immunotherapy presented in the #ASH24 Plenary session. #hematology #leukemia

211534

Reposted by Michael Fisch MD MPH

Ajay Major, MD, MBA @majorajay.bsky.social · 08/12/2024

5-year POLARIX F/U #ASH24 - 5-yr PFS better w/ polaRCHP: 65% v 59% - no difference in OS (7 yr F/U planned) - more LBCL deaths in RCHOP arm, polaRCHP arm w/ less subsequent tx - in underpowered subgroup analysis, polaRCHP PFS/OS better in ABC 6% PFS benefit enough for SOC? #lymsm

1113

Reposted by Michael Fisch MD MPH

Prof Bogda Koczwara @bogda-koczwara.bsky.social · 06/12/2024

If there is only one thing you will read today - make it this one! So many lessons on how to care: -illuminate the personhood -understand life outside the hospital -practical compassion -sit with darkness tinyurl.com/4h2u476m

tinyurl.com

The Care That Saved Me | NEJM

When a pediatric psychologist’s young child becomes seriously ill, she learns unsought lessons about better ways of caring for children and their caregivers in devastating circumstances.

0106

Reposted by Michael Fisch MD MPH

Ken Covinsky @kencovinsky.bsky.social · 02/12/2024

The evidence that social determinants impact health is overwhelming. Excellent viewpoint makes compelling call for fully integrating social determinants into the US Health research priorities. jamanetwork.com/journals/jam...

jamanetwork.com

Prioritizing Research on Social Determinants of Health

This Viewpoint discusses the critical importance of prioritizing social determinants of health in reducing health disparities and advancing health equity.

1117

Reposted by Michael Fisch MD MPH

Gil Morgan MD @weoncologists.bsky.social · 03/12/2024

The annual risk of pancreatic cancer was 0.04% for BRCA1 carriers and 0.09% for BRCA2 carriers, with a cumulative incidence by age 80 of 2.2% and 2.7%, respectively. Risk factors included alcohol consumption and diabetes, with only two cases reporting a first-degree relative with pancreatic cancer.

092

Reposted by Michael Fisch MD MPH

Prof Michael Jefford @michael-jefford.bsky.social · 03/12/2024

and a 2nd paper from the terrific MASCC Survivorship Group, on AI in symptom monitoring ascopubs.org/doi/10.1200/...

074

Reposted by Michael Fisch MD MPH

Prof Michael Jefford @michael-jefford.bsky.social · 03/12/2024

Pleased to share a couple of papers (just out). First from Dr Julia Lai-Kwon, from her PhD work, focused on implementing ePROs to monitor side effects from immunotherapy ➡️Read more: rdcu.be/d2eY9

183

Reposted by Michael Fisch MD MPH

Dawn Hershman, MD, MS, FASCO @drdawnhershman.bsky.social · 02/12/2024

Adherence is such big issue and such a challenging problem solve - we found the same thing in breast cancer patients taking endocrine therapy @swog.org study #S1105- pubmed.ncbi.nlm.nih.gov/32369401/ Lots of work needed to improve outcomes in patients who need oral therapies!!

096

Reposted by Michael Fisch MD MPH

JAMA @jama.com · 02/12/2024

Text message reminders targeting patients who delay refilling their cardiovascular medications did not improve medication adherence based on pharmacy refill data or reduce clinical events at 12 months. ja.ma/4irtinM

06724

Michael Fisch MD MPH @fischmd.bsky.social · 01/12/2024

This paper prompted me to look up “channeling bias” Channeling bias often results from clinicians’ tendencies to prescribe certain treatments to patients with particular prognostic factors or risk levels

171

Reposted by Michael Fisch MD MPH

Megan Ranney MD MPH @meganranney.bsky.social · 01/12/2024

A friend sent this article to me today. It feels like a good moment to remind us: the LLM outperformed physicians on STRUCTURED cases. Someday the AIs may perform better than us in the unstructured, messy, real-world patient encounter...but that day is not today.🩺🛟 jamanetwork.com/journals/jam...

jamanetwork.com

Large Language Model Influence on Diagnostic Reasoning

This randomized clinical trial evaluates the diagnostic performance of physicians with use of a large language model compared with conventional resources.

1514936

Reposted by Michael Fisch MD MPH

Daniel Stover, MD, FASCO @stoverlab.bsky.social · 30/11/2024

Do systemic responses to ICI (eg irAEs) associate w outcomes? Nice use of existing basket studies by @pateloncology.bsky.social @eladsharonmd.bsky.social Razelle Kurzrock et al

1268

Reposted by Michael Fisch MD MPH

Nuria Lopez-Bigas @nlbigas.bsky.social · 27/11/2024

Only a subset of patients respond to immunotherapy Why? Which ones? We conducted an unbiased analysis of response biomarkers and found that hundreds of possible biomarkers collapse into five latent, orthogonal factors that underlie immunotherapy response. www.nature.com/articles/s41...

413246

Reposted by Michael Fisch MD MPH

Janet Freeman-Daily @jfreemandaily.bsky.social · 22/11/2024

Might we implement hashtag cancer communities on Bluesky? They genuinely help stakeholders (esp patients) find info related to a specific cancer. This paper explains how #bcsm #btsm #lcsm and other cancer community hashtags evolved on Twitter. ascopubs.org/doi/pdfdirec...

ascopubs.org

47021

Reposted by Michael Fisch MD MPH

Georg Heinze @georgheinze.bsky.social · 29/11/2024

Two AIs talking about our paper on phases of methodological research in biostatistics doi.org/10.1002/bimj..., created with minimum effort - fascinating and a bit fearsome notebooklm.google.com/notebook/85f...

notebooklm.google.com

051

Reposted by Michael Fisch MD MPH

Thor Halfdanarson @oncothor.bsky.social · 28/11/2024

One of my imaging workhorses in the NET clinic, the CT enterography (CTE). Nothing better to visualize small NETs in the ileum. This patient has at least 30 small lesions that have been stable over many years and monitored with annual CTE. 50% or more of sbNETs are multifocal.

0122